What changed from existing technology?
This study tested a treatment combining a drug that targets inflammation (canakinumab) with radiation and another drug that boosts the immune system (durvalumab) for patients with advanced lung cancer that can't be removed by surgery.
This is the first trial to combine canakinumab with chemoradiation and durvalumab for unresectable stage III non-small cell lung cancer.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
rvival, objective response rate, and safety. Forty-one patients were enrolled, 37 received canakinumab, and 32 comprised the prespecified efficacy population.
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This combination therapy may offer a new treatment option for patients with unresectable stage III non-small cell lung cancer, though further studies are needed to confirm its effectiveness.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.